

Nordeng Hedvig (Orcid ID: 0000-0001-6361-2918)

## Transfer of cetirizine/levocetirizine into human breast milk and estimation of drug exposure to infants through breastfeeding - a human lactation study from the ConcePTION project

Short title: (Levo)cetirizine in human breast milk

Hedvig Nordeng<sup>1</sup>; Christine Wegler<sup>2</sup>; Annika Lindqvist<sup>2,3</sup> Erik Melander<sup>2</sup>, Mikaela Magnusson<sup>4</sup>, Peggy Gandia<sup>5,6</sup>, Alice Panchaud<sup>7,8</sup>, Pawel Baranczewski<sup>2,3</sup>; Olav Spigset<sup>9,10</sup>

1. Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, University of Oslo, Oslo, Norway
2. Department of Pharmacy, Uppsala Drug Optimization and Pharmaceutical Profiling (UDOPP), Uppsala University, SE-75123 Uppsala, Sweden.
3. Department of Pharmacy, SciLifeLab Drug Discovery and Development Platform, Uppsala University, SE-75123 Uppsala, Sweden.
4. Uppsala Biobank, Dag Hammarskjölds väg 38, SE-75185 Uppsala, Sweden
5. Pharmacokinetics and Toxicology laboratory, Toulouse University Hospital, Toulouse, France
6. UMR1436-INTHERES, Toulouse National Veterinary School, France
7. Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland
8. Service of Pharmacy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
9. Department of Clinical Pharmacology, St. Olav University Hospital, Trondheim, Norway
10. Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway

### ORCIDs:

Hedvig Nordeng [0000-0001-6361-2918](https://orcid.org/0000-0001-6361-2918)

Christine Wegler [0000-0002-2810-7518](https://orcid.org/0000-0002-2810-7518)

Annika Lindqvist [0009-0003-2587-8434](https://orcid.org/0009-0003-2587-8434)  
3505

Erik Melander [0009-0002-9981-](https://orcid.org/0009-0002-9981-3505)

Mikaela Magnusson [0000-0003-4347-2094](https://orcid.org/0000-0003-4347-2094)

Peggy Gandia [0000-0002-4385-7894](https://orcid.org/0000-0002-4385-7894)

Alice Panchaud [0000-0001-6086-2401](https://orcid.org/0000-0001-6086-2401)  
6791

Pawel Baranczewski [0000-0001-5772-](https://orcid.org/0000-0001-5772-6791)

Olav Spigset [0000-0001-7902-9014](https://orcid.org/0000-0001-7902-9014)

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/bcpt.13948

**Corresponding Author:**

Hedvig Nordeng  
Pharmacoepidemiology and Drug Safety Research Group,  
Department of Pharmacy, University of Oslo,  
0363 Oslo, Norway

Email: [h.m.e.nordeng@farmasi.uio.no](mailto:h.m.e.nordeng@farmasi.uio.no)

**Keywords:** pharmacokinetics, breast milk, cetirizine, levocetirizine, relative infant dose

**Abstract**

Data on drug transfer into human breast milk is sparse. This study aimed to quantify concentrations of cetirizine and levocetirizine in breast milk and to estimate drug exposure to infants. Breastfeeding women at least eight weeks postpartum and using cetirizine or its pure (R)-enantiomer levocetirizine were eligible to participate. Breast milk samples were collected at six predefined times during a dose interval (0, 2, 4, 8, 12 and 24 hours after drug intake) at steady state. Infant drug exposure was estimated by calculating the absolute infant dose (AID) and the weight-adjusted relative infant dose (RID). In total, 32 women were eligible for final inclusion, 31 women using cetirizine and one woman using levocetirizine. Means of the individual maximum and average cetirizine milk concentrations were 41.0 µg/L and 16.8 µg/L, respectively. Maximum concentrations occurred on average 2.4 hours after intake, and the mean half-life in milk was 7.0 h. Estimated AID and RID for cetirizine in a day were 2.5 µg/kg and 1.9%, respectively. The corresponding values for levocetirizine were 1.1 µg/kg and 1.9%. No severe adverse events were reported. Our findings demonstrate that the transfer of cetirizine and levocetirizine into breast milk is low and compatible with breastfeeding.

**Words: 198 (max 200 words)**

## 1 BACKGROUND

Allergic disorders including allergic rhinitis and urticaria affect up to 20 to 30% of women of reproductive age<sup>1</sup> and may require pharmacological treatment. Antihistamines are one of the most frequently used drugs for these conditions, including during pregnancy and lactation<sup>2</sup> and approximately 2%–3% of women are prescribed antihistamines during the first three months after delivery<sup>3,4</sup>. Second-generation antihistamines are first-line therapy as they are less sedative than the first-generation antihistamines. Despite their frequent use among breastfeeding women, data about the transfer of second-generation antihistamines into human milk is extremely sparse. A systematic literature review from 2022 identified only seven human lactation studies, including in total 25 mother-infant pairs, using cetirizine (three women), clemastine (one woman), ebastine (one woman), epinastine (seven women), loratadine (six women), terfenadine (four women) and triprolidine (three women)<sup>5</sup>. The calculated relative infant dose (RID) was below 5% for all these drugs, ranging from 0.3% for terfenadine to 4.5% for clemastine. For cetirizine, the mean and maximum concentration in breast milk in these women were 21 µg/L and 49 µg/L, respectively<sup>6</sup>. The relative infant dose of cetirizine was 1.8% and the absolute infant dose via breast milk was 3.1 µg/kg/day. The samples, however, were obtained after a single dose of 10 mg cetirizine, and were thus not taken at steady state conditions<sup>6</sup>.

Cetirizine is a racemic mixture of the pharmacologically active (R)-enantiomer and the inactive (S)-enantiomer, whereas levocetirizine consists of the pure (R)-enantiomer. Therefore, levocetirizine is given in half the dose compared to racemic cetirizine; the recommended doses are 5 mg/day and 10 mg/day, respectively<sup>7,8</sup>. No published data on excretion in breast milk is available for levocetirizine. Currently, most market authorization holders of these medications do not recommend use of cetirizine during breastfeeding due to the lack of data on breast milk transfer and safety during breastfeeding<sup>5,7,8</sup>. Reference text books and data bases<sup>9,10</sup>, however, state that use of cetirizine is compatible with breast feeding, considering that the benefits of breastfeeding to the mother and child outweigh the potential risk of medication exposure to the breastfed child. The discrepancies between the manufacturers' product information (see drug label texts in Supplementary Table 1) and clinical guidelines are challenging for patients and prescribers and may prevent optimal treatment of breastfeeding women with allergic conditions. Unfounded concerns about the risks to breastfed infants are unfortunately one of the common reasons for unnecessary cessation of breastfeeding<sup>11</sup>. Human lactation studies, updated information and tailored evidence-based advice is imperative to counteract this.

This study is part of the Innovative Medicines Initiative (IMI) funded ConcePTION project aiming to improve the knowledge about medication use and safety among pregnant and breastfeeding women ([www.imi-conception.eu](http://www.imi-conception.eu), 2019-2024). This includes establishing a European breast milk collection, demonstrating how human lactation studies can be conducted in Europe and developing the standards to do so. More information about this initiative is given in the Supplementary File 1. The initiative is in line with guidelines from the European Medicines Agency (EMA)<sup>12</sup> and US Food and Drug Administration (FDA)<sup>13</sup>.

## **2 OBJECTIVE**

The primary aim of this observational human lactation study was to quantify excretion of cetirizine and levocetirizine into human milk to determine the relative and absolute exposure to breastfed infants. An additional aim was to assess possible infant adverse drug reactions.

## **3 MATERIAL AND METHODS**

### **3.1 Study design and recruitment**

The study was designed as an observational human lactation study in line with European and US regulatory guidelines<sup>12,13</sup>. Individuals using either cetirizine or levocetirizine were eligible for inclusion. Further in this article, we use the term “(levo)cetirizine” to describe cetirizine and levocetirizine together. Participants were recruited from July to December 2021 by means of online advertisements through patient organization websites (e.g., The Norwegian Asthma and Allergy Association and The Norwegian Women's Public Health Association), and social media (e.g. Facebook). These advertisements directed them to the study website to confirm their eligibility, sign online consent forms and fill an online baseline questionnaire. Then, a start-up call provided detailed information about the study procedures and instructions were sent to the participants with the study equipment (Figure 1).

### **3.2 Ethics and approval**

The study was approved by the Regional Committee for Medical and Health Research Ethics in South-East Norway (REK no. 232351, date: 01 June 2021) and the Data Protection Officer at the University of Oslo (date: 03 June 2021). All women gave their written informed consent

prior to inclusion in the study. Moreover, both parents gave their consent for the collection of health information about the infant prior to the study inclusion.

The study was conducted in accordance with the Basic & Clinical Pharmacology & Toxicology policy for experimental and clinical studies<sup>14</sup> and designed in line with the EMA and US FDA recommendations for clinical lactation studies<sup>12,13</sup>. The study is registered in the EU PAS Register (EUPAS46213)<sup>15</sup> and at the Zenodo<sup>16</sup> open science platform.

### **3.3 Inclusion criteria**

Women were eligible to provide milk samples if they were over 18 years, had been using (levo)cetirizine for at least two days — to ensure steady state conditions — and were breastfeeding a healthy infant who was at least eight weeks old. This latter criterion was set to characterize excretion in mature milk, to allow breastfeeding to be well-established and to give the mother time to rest after delivery. Mothers were excluded if they were unable to provide an informed consent. Moreover, mothers with infants who were twins/multiples, were preterm or had malformations or severe illness were not included to avoid the extra burden of study participation.

We aimed to include at least 25 breastfeeding women with a full set of breast milk samples. To reach this sample size, we expected to have to include approximately 30 participants to allow for dropouts and for participants from whom meaningful data could not be provided.

### **3.4 Milk sampling procedure**

The participants were supplied with a milk sampling kit including all necessary sampling equipment (i.e., plastic milk bags, an electric breast milk pump, ice packs and a polystyrene box for shipment of milk samples). They were given oral and written instructions on how to take the breast milk samples at home (approximately 20 ml by sample) and instructed to express a total of six such breast milk samples at predefined time intervals, 0, 2, 4, 8, 12 and 24 hours after dose intake. They were instructed to record the exact time of drug intake and milk sampling. They were advised to express milk from one or both the breasts (i.e. as they usually would breastfeed) until the breast felt empty, and gently turn the container upside down a few times to mix the full volume of pumped milk. Approximately 20 milliliters of the milk were

then transferred into the milk bag and frozen in their home freezer. If someone was not able to express a full 20 ml milk sample, a lower volume was accepted.

They were then asked to store the samples in the provided milk bags in their home freezer until all samples had been collected. When sampling was completed, the samples were packed with ice packs in the polystyrene box and shipped with express delivery to the Uppsala Biobank, Uppsala, Sweden. A pictogram showing the study procedure is presented in Figure 1.

### **3.5 Questionnaire data collection**

Participating mothers reported information about their background and health status at baseline and on the sampling day using online questionnaires. Specifically, they reported their age (years), body weight (kg), height (cm), the infant age (weeks), chronic and acute medical conditions and concomitant drug use. They also reported the birth weight and gestational age of their infant at delivery. On the sampling day, they reported the mode of breastfeeding (exclusively vs. partially breastfed infant), the milk production the previous three days (as before / less than before / more than before), time of (levo)cetirizine intake and time of each milk sampling.

### **3.6 Quantification of cetirizine concentrations in breast milk**

Upon arrival, the samples were examined and aliquoted into maximum 16 x 1 mL aliquots. They were subsequently stored at -80°C until the day of analysis.

Prior to the study, we performed a stability analysis of human breast milk samples spiked with (levo)cetirizine to evaluate whether temperature impacted drug stability in milk. The stability testing showed that the temperature did not impact on drug stability in milk for up to 72 hours at room temperature and seven days at 4 °C<sup>17</sup>.

Measurements of cetirizine levels in milk were carried out using a validated method consisting of liquid chromatography coupled with tandem mass spectrometry (LCMS/MS) in the Department of Pharmacy, Uppsala University (UPPS), Sweden<sup>17</sup>. The method was developed and validated according to the regulatory authorities' recommendations<sup>13,18</sup>. The lower limit of quantification (LLOQ) was set to 0.39 µg/L and the method had a linear range from 0.39 to 194.5 µg/L. The intra-run and inter-run precision and accuracy were ≤ 9%<sup>17</sup>.

### 3.7 Pharmacokinetic analysis and estimation of infant drug exposure

Maximum milk drug concentration ( $C_{\max}$ ) and the corresponding time to maximum concentration ( $t_{\max}$ ) were extracted from the measured values. Other pharmacokinetic variables were calculated using the pharmacokinetic program package Kinetica, version 4.3 (ThermoFisher Scientific, Waltham, MA, USA). The area under the time–milk concentration curve from 0 to 24 hours (AUC) was calculated using a mixed log-linear model. Exact time intervals were used based on the times reported for drug intake and sampling. In a few cases where the 24-hour sample either was lacking or the woman obviously had ingested the morning dose before sampling, we used the concentration at  $t=0$  also at 24 hours, as all samplings took place at steady state conditions. By applying a non-compartment model, the parameter estimate describing the decrease of the log-concentration ( $\lambda_z$ ) was calculated using the best-fit log-linear regression line of the samples representing the elimination phase. The elimination half-life ( $t_{1/2}$ ) was calculated as  $\ln 2 / \lambda_z$ . Average concentration ( $C_{\text{avg}}$ ) in milk throughout the 24-hour sampling period was calculated as the AUC divided by 24 for every individual. No samples had concentrations below the LLOQ, with the exception that all the 17 samples from three women had unmeasurable concentrations. These three women were excluded from the study (Figure 2).

The absolute infant dose (AID) per kg body weight per day when fully breastfed was calculated by multiplying  $C_{\text{avg}}$  by a standard daily milk intake of 150 mL/kg. The relative infant dose (RID) in a day was calculated as the percentage of the AID ( $\mu\text{g/kg/day}$ ) relative to the weight-adjusted maternal dose ( $\mu\text{g/kg/day}$ ). Given the short elimination half-life of (levo)cetirizine, we considered it appropriate also to report the infant dose ingested in a feed. Therefore, we also calculated the AID and RID in a feed in the worst-case scenario of exposure, i.e., when the infant was breastfed at the time of the peak concentration in milk. We then multiplied  $C_{\max}$  with a standard milk intake in a feed of 30 mL/kg.

To be able to compare the pharmacokinetic parameters and the drug exposure estimations among mothers and infants directly, the maternal cetirizine dose was standardized at 10 mg. Thus, for the two mothers with a cetirizine dose of 20 mg/day, all measured concentrations were, given its linear (first order) elimination kinetics<sup>8</sup> divided by two before any pharmacokinetic calculations were made, and a maternal dose of 10 mg/day was used when calculating the RIDs.

### 3.8 Adverse events

At the day of sampling, mothers were asked to report whether their infant had shown any of the following symptoms in the previous 24 hours: drowsiness, sleepiness/sedation, poor feeding/refusal of the breast, rash, bruising/bleeding, constipation, diarrhea, stools with blood or unusual color, or fever. These symptoms were selected as they have previously been reported as adverse drug reactions in breast fed infants<sup>19-21</sup>. The mothers were also asked to comment on reasons for the symptoms. For instance, they could report whether they considered it was more than usual or whether the symptoms could be caused by factors like fever, transitioning to solid foods or weaning. We summarized all reported symptoms irrespective of potential alternative explanations given by the mother to give a full overview of reported symptoms.

## 4 RESULTS

A total of 57 women were screened for eligibility, of whom 42 were initially included and completed the informed consent form. One woman withdrew before completing the baseline questionnaire. Of the 41 women who completed the baseline questionnaire, 37 provided milk samples. Five of these were excluded because they either had undetectable drug concentrations in all samples (n=3) or provided only one milk sample (n=2). The study thus finally included 32 breastfeeding women, 31 women using cetirizine and one woman using levocetirizine. These women provided either 6 (n=29), 5 (n=2) or 4 (n=1) milk samples. A flow diagram presenting the details of inclusion and exclusion is shown in Figure 2. Table 1 summarizes the characteristics of the 32 mother-infant dyads. The mothers had a mean age of 30.3 years (range 22 - 40 years) and a mean body weight of 76.5 kg (range 53 – 110 kg). Their infants had a mean age of 7.8 months (range 8.3 weeks to 21 months), and a mean body weight of 8.3 kg (range 3.7-11.9 kg). Eleven mothers (34 %) reported exclusive breastfeeding whereas the remaining reported partial breastfeeding. The average pumping time to provide a full breast milk sample was 14 minutes.

Figure 3 displays the cetirizine concentration-time profile in breast milk during the 24-hour sampling period (182 milk samples). Table 2 presents pharmacokinetic data for cetirizine in milk. Mean  $C_{max}$  was 41.0 µg/L (range 18.4 -94.7 µg/L), mean  $C_{avg}$  was 16.8 µg/L (range 7.3-42.8 µg/L), mean  $t_{max}$  was 2.4 h (range 1.7-4.6 h) and mean  $t_{1/2}$  was 7.0 h (range 4.3-10.7 h).



Table 3 shows the estimated theoretical AIDs and RIDs for cetirizine in a feed at  $C_{\max}$  and in a day. Assuming exclusive breastfeeding with an average infant milk intake of 150 mL/kg body weight, mean RID in one day was 1.9% (range 0.9–3.8%).

Only one mother was using levocetirizine, at a dose of 5 mg/day. For her, levocetirizine  $C_{\max}$  and  $C_{\text{avg}}$  were 19.3  $\mu\text{g/L}$  and 7.2  $\mu\text{g/L}$ , respectively, whereas  $t_{\max}$  was 1.9 h and  $t_{1/2}$  was 6.2 h. AIDs were 0.6  $\mu\text{g/kg}$  in a feed and 1.1  $\mu\text{g/kg}$  in a day and RIDs were 1.0% in a feed and 1.9% in a day.

Table 4 describes infant symptoms reported by the 31 mothers using cetirizine: 4 had constipation, 3 rashes, 3 poor feeding or refusal of the breast, 2 bruising, 2 fever, 2 sedation, 1 drowsiness. Sixty one percent of infants ( $n=19$ ) did not have any adverse events. In several cases, the mother contributed the symptom to other conditions as the infant having a cold (*fever, sedation, rash*), learning to crawl (*bruising on knees*), weaning (*poor feeding/refusing of the breast*), transitioning to solid foods (*constipation*) and other disease. On the sampling day, 32.3% ( $n=10$ ) of participating mothers estimated their milk production had decreased over the three previous days whereas the remaining mothers declared a normal production. The mother using levocetirizine did not report any adverse events for her infant and described a normal milk production.

## 5 DISCUSSION

The principal finding in the present study is that the transfer of cetirizine and levocetirizine into breast milk is low (RID <2%). These results confirm current clinical practice of considering use of cetirizine to be compatible with breastfeeding and show that it is unlikely that breastfeeding while using cetirizine will pose any significant risk to the infant.

Our results align well with the results from the study in three women by Wilkerson *et al.*, although that study was not performed at steady-state<sup>6</sup> The RIDs were identical (1.8%) and  $C_{\max}$  in our study was 41  $\mu\text{g/L}$  vs. 49  $\mu\text{g/L}$  in the study by Wilkerson *et al.* Relative to the peak plasma concentrations of approximately 300  $\mu\text{g/L}$  in adults<sup>8</sup>, the passage to breast milk is very low (milk/plasma (M/P) concentration ratio ~0.10). We found a milk half-life of 7 hours (SD: 1.5 hours), which is close to the plasma half-life of approximately 8 hours<sup>8</sup>. As expected, the  $t_{\max}$  in milk was delayed in comparison to  $t_{\max}$  in plasma in adults (mean 2.4 hours vs. 1 hour in plasma). Interestingly, in our milk study we found a relatively large variability, in AUC with a 6-fold difference between the lowest and the highest value. In contrast, the variability for

AID and RID was lower, about 4-fold. Nevertheless, even the highest AID and RID values found were reassuringly low. In addition to estimating the clinically relevant relative and absolute infant doses, we also surveyed the breastfed infants for potential adverse drug effects. Bertrand *et al.* recently published baseline rates of common symptoms in breast fed infants without any medication exposure, finding rash (12.1%), irritability (9.4%), constipation (7.8%), poor sleep (7.1%), and fever (6.3%) to be most common ailments the past 2 weeks<sup>21</sup>. In light of these findings, we consider that the reported symptoms in breast-fed infants in our study reflect the normal, expected rates of symptoms in breastfed infants in the general population. As drowsiness and sedation previously have been reported after breast milk exposure to other antihistamines<sup>21</sup>, this is especially reassuring.

The recommended pediatric doses for cetirizine in infants aged six months to 2 year is 0.5 mg/kg/day with a mean dose of 2.3 mg<sup>8</sup>. For an infant weighting 10 kg, the fraction we detected in breast milk would constitute about 1/100 to 1/200 of a neonatal dose. Thus, (levo)cetirizine could clearly be considered a first-line antihistamine for breastfeeding women.

Given the prevalence of allergy and use of antihistamines among women of childbearing age, these results will be reassuring for many post-partum women, and hopefully promote breastfeeding and optimal treatment of allergic disorders while breastfeeding. Equally important, this study, conducted according to European and US standards for human lactation studies, could provide a basis for updating cetirizine product information. Currently, the product information for cetirizine include unpublished data stating that it is excreted in human milk at concentrations representing 25%–90% of those measured in plasma (appendix 1). Such information is not helpful for the estimation of the level of infant exposure or for assessments related to infant safety<sup>22</sup>.

This study has several strengths. It includes intensive sampling with six samples during a period of 24 hours, allowing us to determine concentrations in breast milk at multiple time points throughout the dose interval and to make relatively robust AUC estimations. Moreover, the number of women included was high, thus increasing the reliability of the results. All procedures, including shipment, were piloted to ensure seamless logistics, and an accredited laboratory and biobank facility was utilized. Furthermore, we used a validated, sensitive and robust LC-MS/MS method for analysis<sup>17</sup>. Designing the study to include home sampling and use online follow-up questionnaires enabled nationwide recruitment. Consequently, a rapid recruitment of the target number of participants was possible, and the sampling procedures

including sampling at home had limited interference in the daily life for the breastfeeding mother and her infant.

As shown in Table 2, we detected a moderate variability in the mean and maximum concentrations in breast milk samples between the participants. This may be due to individual pharmacokinetic factors as well as differences in breast milk composition and/or milk sampling. Despite instructions to provide a full breast milk expression sample to obtain a representative sample of a feed, sampling/milk pumping time and milk volume could vary between the women. We did not analyze the milk samples with respect to pH and lipid and protein content, and were thus unable to ascertain whether differences in milk composition impacted the drug concentrations.

When designing the study, we chose not to collect blood samples from the breastfeeding women, which prevented us from calculating M/P ratios. Although the M/P ratio is useful for assessing the extent to which a medication is transferred from blood into the breast milk, it is not a clinically useful parameter to evaluate the risk of infant drug exposure<sup>22</sup>. As the amount of breast milk transfer is largely determined by the concentration of the medication in maternal plasma, even medications with a high M/P ratio may still result in low total drug milk concentrations. The EMA and FDA guidelines underline the importance of minimizing the burden of data collection for the mother while at the same time obtaining adequate data, and generally recommend milk-only studies unless there is a specific reason to conduct another type of study<sup>12,13</sup>.

Although this study has several strengths, there are also some weaknesses that have to be addressed. Only one woman used levocetirizine. However, transfer of a drug from maternal plasma to breast milk is generally believed to be mainly a passive process where the key drug-specific factor determining its excretion is its physico-chemical properties. As the two enantiomers of a drug have identical physico-chemical properties, it is reasonable to assume that although we just were able to include one woman using levocetirizine, the cetirizine results will principally be applicable also for levocetirizine. This is further substantiated by the fact that the RID in a day for levocetirizine was exactly the same as the mean value in the cetirizine group, 1.9%. Thus, even though drug-specific studies are always wanted, we consider that in lack of more levocetirizine data, our cetirizine results could be considered valid also for levocetirizine. As the analytical method was not enantioselective, we cannot verify that all women used the drug stated. However, as all results were plausible, we have no reason to believe that any of the women had mixed up cetirizine with levocetirizine, or vice versa.

Nevertheless, analyzing the (R) and (S) enantiomers separately would have provided even more detailed information about the excretion of racemic cetirizine in breast milk.

Because we relied on participants' self-sampling and reporting at home, we were not able to observe and assess how well the women complied with the study procedures and instructions. Inaccurate recordings of timing of cetirizine intake and milk sampling or other deviations from instructions (e.g. lack of a full breast milk sample) could potentially influence the estimates presented, and explain some of the variability. However, we excluded subjects with obvious protocol deviations or unreliable results (Figure 2), and the high number of samples included would counteract single reporting errors having a large impact on results. Our results must be interpreted with these limitations in mind.

## 6. CONCLUSION

This study shows that the transfer of cetirizine and levocetirizine into breast milk is low, with an average RID below 2%, and an average absolute daily infant dose being less than 3 µg/kg/day. No severe adverse events were reported in the breast-fed infants, and the reported symptoms reflected well the normal expected rates of minor ailments in healthy breastfed infants. These results confirm current clinical practice of considering cetirizine and levocetirizine to be compatible with breastfeeding and shows that it is unlikely that breastfeeding while using cetirizine or levocetirizine will pose any significant risk to the infant.

## ACKNOWLEDGEMENTS

The authors are grateful to the participating mothers for the milk donations. The research leading to these results was conducted as part of the ConcePTION consortium. The authors thank the IMI-ConcePTION WP4/3 members in particular *Mats Hansson* (WP4 lead), *Pieter Annaert* (WP3 lead) for valuable and stimulating discussions, *Jennifer Drevin* (recruitment video), and especially to former master student *Basma Kousa* who performed her master thesis in pharmacy as part of this study and former PhD student *Maria Bich-Thuy Truong* and post doc *Marion Taine* at the University of Oslo. This paper only reflects the personal views of the stated authors.

## **CONFLICT OF INTEREST**

The authors have no conflicts of interest to declare.

## **FUNDING**

The ConcePTION project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 821520. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program and EFPIA.

## **DATA AVAILABILITY STATEMENT**

Data not available - participant consent

## **IRB STATEMENT**

The study was approved by the Regional Committee for Medical and Health Research Ethics in South-East Norway (REK no. 232351, date: 01 June 2021) and the Data Protection Officer at the University of Oslo (date: 03 June 2021). See also pt. 3.2 Ethics and approval.

## REFERENCES

1. Pali-Scholl I, Namazy J, Jensen-Jarolim E. Allergic diseases and asthma in pregnancy, a secondary publication. *World Allergy Organ J.* 2017;10(1):10. doi:10.1186/s40413-017-0141-8.
2. Nordeng H, van Gelder M. Drug Utilisation Studies in Pregnancy. In: Elseviers M, Wettermark B, Almarsdóttir A B, Andersen M, Benko R, Bennie M, Eriksson I, Godman B, Krska J, Poluzzi E, Taxis K, Vlahovic-Palcevski V, Vander Stichele R (eds.) *Drug Utilization Research: Methods and Applications*. Publisher John Wiley & Sons Inc.; 2023.
3. Engeland A, Bjørge T, Klungsøyr K, Hjellvik V, Skurtveit S, Furu K. Trends in prescription drug use during pregnancy and postpartum in Norway, 2005 to 2015. *Pharmacoepidemiol Drug Saf.* 2018;27(9):995-1004.
4. Stephansson O, Granath F, Svensson T, Haglund B, Ekblom A, Kieler H. Drug use during pregnancy in Sweden – assessed by the prescribed drug register and the medical birth register. *Clin Epidemiol.* 2011;3:43-50.
5. Ngo E, Spigset O, Lupattelli A, et al. Antihistamine use during breastfeeding with focus on breast milk transfer and safety in humans: A systematic literature review. *Basic Clin Pharmacol Toxicol.* 2022;130(1):171-181. doi:10.1111/bcpt.13663.
6. Wilkerson H, Datta P, Rewers-Felkins K, Baker T, Hale TW. Maternal Transfer of Cetirizine Into Human Milk. *J Hum Lact.* 2021;37(1):135-138.
7. United States Food and Drug Administration. Xyzal (Levocetirizine dihydrochloride) 5 mg tablets 2.5 mg/5 ml (0.5 mg/mL) oral solution (Accessed 27/08/2023).  
[www.accessdata.fda.gov/drugsatfda\\_docs/label/2008/022064s009lbl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022064s009lbl.pdf).
8. United States Food and Drug Administration. Product label 70-4573-00-5 - ZYRTEC (cetirizine hydrochloride). Tablets and Syrup for oral use. (Accessed 27/08/2023).  
[www.accessdata.fda.gov/drugsatfda\\_docs/label/2002/19835s15,%2020346s8lbl.p  
df](http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/19835s15,%2020346s8lbl.pdf)

9. Hale TW, Krutsch K. *Hale's medications and mothers' milk*, 2023. 20th ed. New York, NY: Springer Publishing Company. 2022.
10. Drugs and Lactation Database (LactMed). [database on the Internet]. National Library of Medicine. Available from: [www.toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT](http://www.toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT).
11. Odom EC, Li R, Scanlon KS, Perrine CG, Grummer-Strawn L. Reasons for earlier than desired cessation of breastfeeding. *Pediatrics*. 2013;131(3):e726-e732.
12. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). 2019. (Accessed 27/08/2023). [www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidelines-good-pharmacovigilance-practices-gvp-introductory-cover-note-last-updated-chapter-piii\\_en.pdf](http://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guidelines-good-pharmacovigilance-practices-gvp-introductory-cover-note-last-updated-chapter-piii_en.pdf).
13. United States Food and Drug Administration. Clinical lactation studies: considerations for study design. 2019. (Accessed 27/08/2023). [www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-lactation-studies-considerations-study-design](http://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-lactation-studies-considerations-study-design).
14. Tveden-Nyborg P, Bergmann TK, Jessen N, Simonsen U, Lykkesfeldt J. BCPT 2023 policy for experimental and clinical studies. *Basic Clin Pharmacol Toxicol*. 2023 Sep 21. doi: 10.1111/bcpt.13944.
15. Levocetirizine/cetirizine levels in human milk – an observational, clinical study among breastfeeding women. EU PAS Register Number 46213, registered 11.03.2022. (Accessed 27/08/2023). [www.encepp.eu](http://www.encepp.eu).
16. Nordeng H. Levocetirizine/cetirizine levels in human milk – an observational, clinical study among breastfeeding women. *Zenodo*. (Accessed 27/08/2023). <https://doi.org/10.5281/zenodo.6345336>.
17. Wegler C, Saleh A, Lindqvist A, Nordeng H, Smeraglia J, Baranczewski P. Simple and rapid quantification of cetirizine, venlafaxine, and O-desmethylvenlafaxine in human breast milk, and metformin in human milk and plasma with UHPLC-MS/MS. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2022;1205:123340.
18. United States Food and Drug Administration, Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Center for Veterinary

Medicine (CVM). Bioanalytical method validation, Guidance for Industry, FDA-2013-D-1020, 2018. (Accessed 27/08/2023). (<https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf>)

19. Bertrand K, Kelly A, Chambers CD. The prevalence of nonserious events in a cohort of breastfed infants. *Breastfeed Med*. 2023;18(1):43-47.
20. Anderson PO, Pochop SL, Manoguerra AS. Adverse drug reactions in breastfed infants: Less than imagined. *Clin Pediatr* 2003;42(4):325–340.
21. Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. *Am J Obstet Gynecol* 1993;168(5): 1393–1399.
22. Cardoso E, Monfort A, Ferreira E, Nordeng H, Winterfeld U, Allegaert K, Gandia P, Guidi M, Panchaud A. Maternal drugs and breastfeeding: Risk assessment from pharmacokinetics to safety evidence - A contribution from the ConcePTION project. *Therapie*. 2023:S0040-5957(23)00025-2.



**Table 1** Demographics of the study participants (n = 32) and their infants (n = 32) at the time of study inclusion. Subject No. 1-29 used cetirizine 10 mg/day, subject No. 30-31 used cetirizine 20 mg/day and subject No. 32 used levocetirizine 5 mg/day.

Subject No.	Maternal		Infant		Mode of breast-feeding	Maternal co-medication
	Age (years)	Weight (kg)	Age (months)	Weight (kg)		
1	27	64	10.0	9.2	Partial	Fluticasone <sup>a</sup>
2	25	100	5.4	8.0	Exclusive	-
3	29	71	5.5	8.0	Exclusive	Salmeterol/fluticasone <sup>b</sup> ; desogestrel
4	33	76	10.0	8.9	Partial	Desogestrel
5	24	53	11.7	11.8	Partial	-
6	37	89	1.4	5.2	Exclusive	-
7	29	67	7.0	7.6	Partial	-
8	37	59	6.2	7.6	Partial	Mometasone <sup>a</sup>
9	28	83	13.5	9.5	Partial	Desogestrel
10	29	71	4.5	6.8	Exclusive	Mometasone <sup>a</sup>
11	33	110	11.5	7.7	Partial	Levonorgestrel IUD; labetalol; levothyroxine; amlodipine
12	40	88	21.2	10.8	Partial	Fluticasone <sup>a</sup>
13	23	58	6.0	7.0	Partial	-
14	27	63	3.7	7.9	Exclusive	-
15	35	98	8.2	10.2	Partial	Levonorgestrel IUD
16	31	72	6.6	7.9	Partial	Fluticasone <sup>a</sup> ; Levonorgestrel IUD
17	31	69	2.8	7.6	Exclusive	-
18	33	88	11.8	11.1	Partial	Levothyroxine
19	22	87	4.9	6.9	Exclusive	Medroxyprogesteron
20	32	93	6.5	6.7	Partial	Desogestrel
21	29	80	8.2	8.4	Partial	-
22	27	82	2.1	5.4	Exclusive	Desogestrel
23	25	64	11.2	9.5	Partial	-
24	33	59	15.7	11.9	Partial	Dexchlorpheniramine
25	32	75	9.1	9.1	Partial	Escitalopram; pantoprazole
26	27	100	5.5	6.9	Exclusive	Allergen extract of house dust mites
27	32	55	10.5	8.8	Partial	-
28	32	65	6.0	7.0	Partial	-
29	34	90	4.0	5.8	Exclusive	-
30	31	76	1.8	3.7	Exclusive	-
31	29	74	8.5	10.1	Partial	-
32	34	79	13.0	11.5	Partial	-
<b>Mean (SD)</b>	<b>30.3 (4.2)</b>	<b>76.5 (14.7)</b>	<b>7.8 (4.5)</b>	<b>8.3 (2.0)</b>		
<b>Median</b>	<b>31</b>	<b>74.5</b>	<b>6.8</b>	<b>8.0</b>		
<b>IQR</b>	<b>(27; 33)</b>	<b>(63; 88)</b>	<b>(5.3; 10.7)</b>	<b>(7.0; 9.5)</b>		

*BMI* body mass index; *IUD* intrauterine device; *IQR* interquartile range; *SD* standard deviation.

<sup>a</sup> For intranasal use. <sup>b</sup> For inhalation

**Table 2** Pharmacokinetic data of cetirizine in breast milk at steady state in 31 women using cetirizine. Concentrations were adjusted to an intake of 10 mg/day.

Subject No.	C <sub>max</sub> (µg/L)	t <sub>max</sub> (h)	t <sub>1/2</sub> (h)	AUC (µg·h/L)	C <sub>avg</sub> (µg/L)
1	33.6	2.0	6.1	289	12.0
2	35.8	1.9	8.0	317	13.2
3	44.7	1.7	7.4	447	18.6
4	37.9	2.6	6.3	387	16.1
5	39.7	2.2	6.7	314	13.1
6	33.8	4.1	8.8	470	19.6
7	30.2	2.0	5.2	250	10.4
8	64.7	1.9	5.1	492	20.5
9	24.5	4.6	8.3	312	13.0
10	48.9	1.8	6.2	459	19.1
11	42.8	2.9	7.5	461	19.2
12	18.4	4.5	5.0	174	7.3
13	42.1	2.0	7.9	433	18.0
14	45.4	1.9	7.2	480	20.0
15	24.3	2.4	7.1	259	10.8
16	33.2	3.8	9.6	398	16.6
17	31.7	2.1	6.4	364	15.2
18	31.2	2.5	7.9	314	13.1
19	27.5	2.0	6.5	228	9.5
20	61.3	2.6	7.2	609	25.4
21	42.9	2.3	9.5	480	20.0
22	28.4	2.0	4.3	214	8.9
23	32.6	2.2	6.6	327	13.6
24	49.8	1.9	5.1	360	15.0
25	23.9	1.9	5.8	212	8.8
26	42.1	1.7	6.2	302	12.6
27	37.5	2.1	5.4	315	13.1
28	63.7	1.9	6.2	639	26.6
29	72.1	2.0	10.7	827	34.5
30 <sup>a</sup>	94.7	1.8	8.1	1028	42.8
31 <sup>a</sup>	31.5	1.9	6.1	306	12.8
<b>Mean (SD)</b>	<b>41.0 (16.2)</b>	<b>2.4 (0.8)</b>	<b>7.0 (1.5)</b>	<b>404 (184)</b>	<b>16.8 (7.7)</b>
<b>(Min; Max)</b>	<b>(18.4; 94.7)</b>	<b>(1.7; 4.6)</b>	<b>(4.3; 10.7)</b>	<b>(174; 1028)</b>	<b>(7.3; 42.8)</b>

AUC area under the milk concentration-time curve from 0-24 hours; C<sub>avg</sub> average concentration; C<sub>max</sub> maximum concentration; Max maximum; Min minimum; SD standard deviation; t<sub>max</sub> time to reach the maximum concentration; t<sub>1/2</sub> elimination half-life

<sup>a</sup> Maternal dose was 20 mg/day. All concentrations were divided by 2 to adjust them to a dose to 10 mg/day. Pharmacokinetic calculations were based on these adjusted concentrations.

**Table 3** Estimated absolute and relative infant doses of cetirizine in 31 breastfed infants.

Subject No.	Absolute infant dose ( $\mu\text{g/kg}$ )		Relative infant dose (%) <sup>a</sup>	
	In a feed at $C_{\max}^b$	In a day <sup>c</sup>	In a feed at $C_{\max}^b$	In a day <sup>c</sup>
1	1.0	1.8	0.6	1.2
2	1.1	2.0	1.1	2.0
3	1.3	2.8	1.0	2.0
4	1.1	2.4	0.9	1.8
5	1.2	2.0	0.6	1.0
6	1.0	3.0	0.9	2.6
7	0.9	1.6	0.6	1.1
8	1.9	3.1	1.1	1.8
9	0.7	1.9	0.6	1.7
10	1.5	2.9	1.0	2.0
11	1.3	2.9	1.4	3.2
12	0.6	1.1	0.5	1.0
13	1.3	2.7	0.7	1.6
14	1.4	3.1	0.9	2.0
15	0.7	1.7	0.7	1.6
16	1.0	2.5	0.7	1.8
17	1.0	2.3	0.7	1.6
18	0.9	1.9	0.9	1.7
19	0.8	1.5	0.8	1.4
20	1.8	3.8	1.5	3.0
21	1.3	3.0	1.1	2.5
22	0.9	1.3	0.6	0.9
23	1.0	2.0	0.8	1.6
24	1.5	2.3	1.0	1.6
25	0.7	1.3	0.7	1.3
26	1.3	1.8	0.7	1.0
27	1.1	2.0	0.7	1.3
28	1.9	4.0	1.7	3.5
29	2.2	5.2	1.6	3.7
30 <sup>d</sup>	2.8	6.4	0.8	3.8
31 <sup>d</sup>	0.9	1.9	0.4	1.4
<b>Mean (SD)</b>	<b>1.2 (0.5)</b>	<b>2.5 (1.2)</b>	<b>0.9 (0.3)</b>	<b>1.9 (0.8)</b>
<b>(Min; Max)</b>	<b>(0.6; 2.8)</b>	<b>(1.1; 6.4)</b>	<b>(0.4; 1.7)</b>	<b>(0.9; 3.8)</b>

Max maximum; Min minimum; SD standard deviation

<sup>a</sup> Infant dose per kg body weight, expressed as a percentage of the maternal dose per kg body weight

<sup>b</sup> Assuming a milk intake of 30 mL/kg body weight, calculated at milk  $C_{\max}$

<sup>c</sup> Assuming a milk intake of 150 mL/kg body weight, calculated by means of milk  $C_{\text{avg}}$

<sup>d</sup> Maternal dose was 20 mg/day. All relevant values are adjusted to a maternal dose of 10 mg/day

**Table 4** Reported symptoms the day before the milk sampling day in 31 breastfed infants of women using cetirizine while breastfeeding.\*

Reported symptoms	n=31 N (%)
<i>Any symptoms</i>	12 (38.7%)
Constipation	4 (12.9%)
Rash	3 (9.7%)
Poor feeding or refusal of the breast	3 (9.7%)
Bruising, or bleeding	2 (6.5%)
Fever	2 (6.5%)
Sedation	2 (6.5%)
Drowsiness	1 (3.2%)
Diarrhea	0 (0%)
Stools with blood or abnormal color	0 (0%)

\*In several cases, alternative explanations for the symptoms were present (i.e. cold, infection, weaning, learning to crawl, other disease). All reported symptoms listed are listed, irrespective of their origin, for full data transparency.




Figure 1. Pictogram showing the study procedure.




Figure 2. Flow diagram of the women and milk samples included in the study.




Figure 3. 24-hour concentration-time profile of cetirizine in breast milk from 31 women at steady state, adjusted to an intake of 10 mg/d.

# Transfer of cetirizine/levocetirizine into human breast milk and estimation of drug exposure to infants through breastfeeding - a human lactation study from the ConcePTION project

Hedvig Nordeng<sup>1</sup>; Christine Wegler<sup>2</sup>; Annika Lindqvist<sup>2,3</sup> Erik Melander<sup>2</sup>, Mikaela Magnusson<sup>4</sup>, Peggy Gandia<sup>5,6</sup>, Alice Panchaud<sup>7,8</sup>, Pawel Baranczewski<sup>2,3</sup>; Olav Spigset<sup>9,10</sup>



## Graphical Abstract Text

This study examined the presence of cetirizine and levocetirizine in breast milk. Drug levels in breast milk were low, with estimated doses of 2.5  $\mu\text{g/kg/day}$  for cetirizine (relative infant dose: 1.9%). Values for levocetirizine were 1.1  $\mu\text{g/kg/day}$  and 1.9%. No severe adverse events were reported, affirming their compatibility with breastfeeding.